five other products in commercial development....
Ethyol mentioned first......
MEDI-507, "antigen-specific hyporesponsiveness", mentioned second.
(yahoooo!)
Psoriasis. Next year, RA. GvH sidelined (which I think is great). Seeing a good safety profile, no infusion-related issues, no significant T cell depletion. What they have seen is modest, transient depletion. For SQ study, pushing to two higher doses to see if they can reach dose limiting toxicity.
(if it selectively depletes antigen-specific responses, why would one want to push to the point where dose-limiting toxicity is observed??)
By summer, expect both phase II studies to be complete. Expect to push into phase III by the end of next year.
So...... Ethyol doesn't count IMO, as it's already commercialized. MEDI-507 therefore, in my book, first out of their mouths. |
